Friday, 16 October 2026European Markets

SALMAR And Coca-ColaEuropacif Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(VIANEWS) - SALMAR (SALM.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Consumer Defensive sector.

Financial Asset Price Forward Dividend Yield Return on Equity
SALMAR (SALM.OL) kr458.70 4.46% 18.21%
Coca-ColaEuropacif (CCEP.AS) €60.10 3.09% 20.75%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. SALMAR (SALM.OL)

4.46% Forward Dividend Yield and 18.21% Return On Equity

SalMar ASA, an aquaculture company, produces and sells farmed salmon in Asia, the United States, Canada, Norway, rest of Europe, and internationally. It is involved in the broodfish, lumpfish, and smolt production activities; and marine-phase farming, harvesting, processing, and selling farmed salmon. The company sells its products through in-house salesforce and/or through close partners. SalMar ASA was founded in 1991 and is headquartered in Kverva, Norway.

Earnings Per Share

As for profitability, SALMAR has a trailing twelve months EPS of kr26.69.

PE Ratio

SALMAR has a trailing twelve months price to earnings ratio of 17.19. Meaning, the purchaser of the share is investing kr17.19 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.21%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 37.4%, now sitting on 20.04B for the twelve trailing months.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Jun 9, 2023, the estimated forward annual dividend rate is 20 and the estimated forward annual dividend yield is 4.46%.

More news about SALMAR.

2. Coca-ColaEuropacif (CCEP.AS)

3.09% Forward Dividend Yield and 20.75% Return On Equity

Coca-Cola Europacific Partners PLC, together with its subsidiaries, produces, distributes, and sells a range of non-alcoholic ready to drink beverages. It offers flavours, mixers, and energy drinks; soft drinks, waters, enhanced water, and isotonic drinks; and ready-to-drink tea and coffee, juices, and other drinks. The company provides its products under the Coca-Cola, Diet Coke, Coca-Cola Zero Sugar, Fanta, Sprite, Monster Energy, Coca-Cola Energy, Relentless, nalu, URGE, BURN, Kuli, REIGN, POWERADE, Appletiser, Schweppes, FINLEY, mezzo mix, Royal Bliss, Lift, Vio SCHORLE, Coca-Cola Signature Mixers, NORDIC MIST, smartwater, Chaudfontaine, AQUARIUS, VILAS del Turbon, BONAQUA, Apollinaris, Krystal, Honest, Costa Coffee, Fuzetea, CHAQWA, NESTEA, Capri-Sun, Oasis, Minute Maid, MER, and Tropico brands. In addition, it engages in the bottling and other operations. The company was formerly known as Coca-Cola European Partners plc and changed its name to Coca-Cola Europacific Partners PLC in May 2021. Coca-Cola Europacific Partners PLC was founded in 1904 and is based in Uxbridge, the United Kingdom.

Earnings Per Share

As for profitability, Coca-ColaEuropacif has a trailing twelve months EPS of €3.29.

PE Ratio

Coca-ColaEuropacif has a trailing twelve months price to earnings ratio of 18.27. Meaning, the purchaser of the share is investing €18.27 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.75%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 15.2%, now sitting on 17.32B for the twelve trailing months.

Volume

Today's last reported volume for Coca-ColaEuropacif is 4152 which is 84.68% below its average volume of 27112.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Coca-ColaEuropacif's stock is considered to be oversold (<=20).

More news about Coca-ColaEuropacif.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com